On March 29, 2022 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported details for its planned Virtual R&D Investor Event on Friday, April 8, 2022, beginning at 4:05 PM EDT (Press release, Cogent Biosciences, MAR 29, 2022, View Source [SID1234611086]). Attendees can register HERE for the event.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cogent will share updates on recent progress, including additional nonclinical data demonstrating the potential of bezuclastinib as a best-in-class KIT mutant inhibitor, outline its strategy and focus to create best-in-class small molecules for genetically defined diseases, and present early data from its growing pipeline of novel, small molecule targeted therapy programs, including Fibroblast Growth Factor Receptor 2 (FGFR2).
Featured speakers include:
Andrew Robbins, President and Chief Executive Officer
John Robinson, PhD, Chief Scientific Officer
Jessica Sachs, MD, Chief Medical Officer
Access to the webcast will be available on the investor relations section of Cogent’s website, including an archived replay of the webcast at View Source
The Virtual Investor R&D Event will coincide with the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, at which Cogent will share data from two poster presentations. The first poster presentation (Abstract 147) will highlight new nonclinical data on the unique properties of bezuclastinib that differentiate it from other KIT inhibitors. Bezuclastinib is currently under clinical investigation in Advanced Systemic Mastocytosis (NCT04996875), Nonadvanced Systemic Mastocytosis (NCT05186753), and imatinib-resistant Gastrointestinal Stromal Tumors (GIST) (NCT05208047). A second poster presentation (Abstract 167) will reveal in vitro and in vivo characteristics of a novel series of FGFR inhibitors with potency against clinically relevant mutations. The AACR (Free AACR Whitepaper) poster presentations will be made available through the AACR (Free AACR Whitepaper) conference website on Friday, April 8 at 1:00 PM EDT, and the in-person poster presentations will occur Sunday, April 10, 1:30 – 5:00 PM CDT.